Cutaneous Lupus Erythematosus Clinical Trials

4 recruiting

Cutaneous Lupus Erythematosus Trials at a Glance

11 actively recruiting trials for cutaneous lupus erythematosus are listed on ClinicalTrialsFinder across 6 cities in 41 countries. The largest study group is Phase 3 with 4 trials, with the heaviest enrollment activity in Los Angeles, Sofia, and Philadelphia. Lead sponsors running cutaneous lupus erythematosus studies include EMD Serono Research & Development Institute, Inc., Bristol-Myers Squibb, and Biogen.

Browse cutaneous lupus erythematosus trials by phase

Treatments under study

About Cutaneous Lupus Erythematosus Clinical Trials

Looking for clinical trials for Cutaneous Lupus Erythematosus? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Cutaneous Lupus Erythematosus trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Cutaneous Lupus Erythematosus clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 2Phase 3

A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Biogen450 enrolled314 locationsNCT05531565
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled3 locationsNCT07332481
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

Cutaneous Lupus ErythematosusSystematic Lupus Erythematosus
EMD Serono Research & Development Institute, Inc.202 enrolled3 locationsNCT07355218
Recruiting
Phase 2

A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)

Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH56 enrolled86 locationsNCT06980805
Recruiting
Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus

Systemic Lupus ErythematosusSLESLE (Systemic Lupus)+2 more
Ventus Therapeutics U.S., Inc.24 enrolled27 locationsNCT07260877
Recruiting
Phase 4

A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132

Systemic Lupus Erythematosus (SLE)Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Bristol-Myers Squibb35 enrolled4 locationsNCT06875960
Recruiting

Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus (CLE)
University of Pennsylvania700 enrolled2 locationsNCT01510067
Recruiting
Phase 3

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus
AstraZeneca302 enrolled272 locationsNCT06015737
Recruiting

Research Accelerated by You Lupus Registry

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Cutaneous Lupus Erythematosus (CLE)
Lupus Foundation of America10,000 enrolled1 locationNCT06927219
Recruiting
Early Phase 1

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Cutaneous Lupus Erythematosus
Noxopharm Limited32 enrolled1 locationNCT07072611
Recruiting
Not Applicable

Deep Phenotyping of Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus
Centre for Human Drug Research, Netherlands40 enrolled1 locationNCT06411106